Drugs / Vestipitant
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01290133 | May → Oct 2011 | — | Accenture | Completed | No outcome recorded |
| Phase 27 trials · 1 met primary | ||||||
| Phase 2 | NCT01507194 | Feb → Aug 2012 | — | Accenture | Completed | Met primary |
| Phase 2 | NCT00992160 | May → Sep 2009 | sleep disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00394056 | Dec 2006 → Aug 2009 | tinnitus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00600990 | Dec 2004 → Jul 2006 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00343707 | Nov 2004 → Nov 2005 | anxiety disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00403962 | Nov 2004 → Aug 2005 | social phobia | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00048204 | Nov 2002 → Sep 2003 | major depressive disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00606697 Comparator | Dec 2007 → May 2008 | sleep disorder, initiating and maintaining sleep | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vestipitant | “a Single Intravenous Dose of the Captisol™ Formulation of Vestipitant (GW597599) in Healthy Adult Subjects” NCT01290133 ↗5“Vestipitant (15mg/Day) for the Treatment of Primary Insomnia” NCT00992160 ↗ |
| Known as | GW-597588B | ChEMBL registry synonym — accepted as the source's own label CHEMBL522987 ↗ |
| Known as | GW597599 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00606697 ↗ |
| Known as | GW597599B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00048204 ↗ |
| Known as | Vestipitant mesilate | ChEMBL registry synonym — accepted as the source's own label CHEMBL522987 ↗ |
| Known as | VESTIPITANT MESYLATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL522987 ↗ |
| Action | Inhibit | “Neurokinin 1 receptor antagonist” CHEMBL522987 ↗1“NK1 receptor antagonist” NCT00394056 ↗ |
| Modality | Small molecule | — CHEMBL522987 ↗ |
| Route | Oral | “Oral (25 mg)” NCT00600990 ↗ |
| Target | TACR1 | “Neurokinin 1 receptor antagonist” CHEMBL522987 ↗ |